Cannabinoids in Late Life Parkinson's Disease and Dementia: Biological Pathways and Clinical Challenges.
CBD
THC
cannabinoids
cannabis
elderly
neurological disorders
psychiatric disorders
Journal
Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646
Informations de publication
Date de publication:
22 Nov 2022
22 Nov 2022
Historique:
received:
23
10
2022
revised:
16
11
2022
accepted:
18
11
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
24
12
2022
Statut:
epublish
Résumé
The use of cannabinoids as therapeutic drugs has increased among aging populations recently. Age-related changes in the endogenous cannabinoid system could influence the effects of therapies that target the cannabinoid system. At the preclinical level, cannabidiol (CBD) induces anti-amyloidogenic, antioxidative, anti-apoptotic, anti-inflammatory, and neuroprotective effects. These findings suggest a potential therapeutic role of cannabinoids to neurodegenerative disorders such as Parkinson's disease (PD) and Alzheimer. Emerging evidence suggests that CBD and tetrahydrocannabinol have neuroprotective therapeutic-like effects on dementias. In clinical practice, cannabinoids are being used off-label to relieve symptoms of PD and AD. In fact, patients are using cannabis compounds for the treatment of tremor, non-motor symptoms, anxiety, and sleep assistance in PD, and managing responsive behaviors of dementia such as agitation. However, strong evidence from clinical trials is scarce for most indications. Some clinicians consider cannabinoids an alternative for older adults bearing Parkinson's disease and Alzheimer's dementia with a poor response to first-line treatments. In our concept and experience, cannabinoids should never be considered a first-line treatment but could be regarded as an adjuvant therapy in specific situations commonly seen in clinical practice. To mitigate the risk of adverse events, the traditional dogma of geriatric medicine, starting with a low dose and proceeding with a slow titration regime, should also be employed with cannabinoids. In this review, we aimed to address preclinical evidence of cannabinoids in neurodegenerative disorders such as PD and AD and discuss potential off-label use of cannabinoids in clinical practice of these disorders.
Identifiants
pubmed: 36552056
pii: brainsci12121596
doi: 10.3390/brainsci12121596
pmc: PMC9775654
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Déclaration de conflit d'intérêts
The authors have no conflict of interest to report.
Références
Br J Pharmacol. 2015 Oct;172(20):4790-805
pubmed: 26218440
Ageing Res Rev. 2020 May;59:101041
pubmed: 32109605
Annu Rev Neurosci. 2012;35:529-58
pubmed: 22524785
Pharmacol Ther. 2013 Apr;138(1):18-37
pubmed: 23261685
Eur J Neurosci. 2001 Dec;14(11):1827-32
pubmed: 11860478
Mov Disord. 2002 Nov;17(6):1180-7
pubmed: 12465055
Brain Sci. 2021 Sep 14;11(9):
pubmed: 34573232
J Alzheimers Dis. 2015;43(3):977-91
pubmed: 25125475
Parkinsonism Relat Disord. 2022 Sep;102:124-130
pubmed: 36038457
J Neural Transm (Vienna). 2002 May;109(5-6):777-87
pubmed: 12111467
Int J Mol Sci. 2017 Jul 31;18(8):
pubmed: 28788104
J Mol Med (Berl). 2006 Mar;84(3):253-8
pubmed: 16389547
PLoS Med. 2021 Mar 29;18(3):e1003524
pubmed: 33780450
Eur J Intern Med. 2018 Mar;49:12-19
pubmed: 29307505
J Psychopharmacol. 2009 Nov;23(8):979-83
pubmed: 18801821
PLoS One. 2013 Apr 24;8(4):e61462
pubmed: 23637839
Acta Biochim Biophys Sin (Shanghai). 2017 Oct 1;49(10):853-866
pubmed: 28981597
J Neural Transm (Vienna). 2022 Oct;129(10):1247-1256
pubmed: 35859051
Cannabis Cannabinoid Res. 2017 Jun 01;2(1):139-154
pubmed: 28861514
Open Biol. 2016 Apr;6(4):150276
pubmed: 27248801
PLoS One. 2021 May 13;16(5):e0251677
pubmed: 33984046
ACS Chem Neurosci. 2012 May 16;3(5):356-63
pubmed: 22860203
J Am Geriatr Soc. 2013 Mar;61(3):335-40
pubmed: 23452054
Pharmacol Toxicol. 2003 Aug;93(2):66-70
pubmed: 12899667
J Psychopharmacol. 2012 Jan;26(1):23-39
pubmed: 21768162
Pharmacol Biochem Behav. 2022 Feb;213:173339
pubmed: 35077729
J Cannabis Res. 2021 Jul 2;3(1):22
pubmed: 34215346
J Am Geriatr Soc. 2005 Feb;53(2):233-41
pubmed: 15673346
Neurobiol Dis. 2016 Oct;94:179-95
pubmed: 27373843
Drugs Aging. 2021 Oct;38(10):887-910
pubmed: 34235645
Int J Geriatr Psychiatry. 1997 Sep;12(9):913-9
pubmed: 9309469
Methods Mol Med. 2006;123:1-17
pubmed: 16506399
Int J Mol Sci. 2022 Aug 21;23(16):
pubmed: 36012711
Physiol Rev. 2009 Jan;89(1):309-80
pubmed: 19126760
Addiction. 2017 Mar;112(3):516-525
pubmed: 27767235
Biology (Basel). 2022 Mar 14;11(3):
pubmed: 35336814
Neuroscience. 2022 Aug 21;498:64-72
pubmed: 35792194
J Am Geriatr Soc. 2021 Sep;69(9):2591-2597
pubmed: 34037250
Nature. 1993 Sep 2;365(6441):61-5
pubmed: 7689702
Gerontologist. 2020 May 15;60(4):e232-e241
pubmed: 31087043
J Pain Res. 2022 Feb 02;15:267-286
pubmed: 35140513
Lancet. 2015 Aug 29;386(9996):896-912
pubmed: 25904081
J Psychoactive Drugs. 2019 Nov-Dec;51(5):400-404
pubmed: 31264536
J Alzheimers Dis. 2016 Oct 4;54(3):903-912
pubmed: 27567873
J Neurol Neurosurg Psychiatry. 1994 Jun;57(6):672-81
pubmed: 7755681
Front Neurosci. 2022 Sep 02;16:962922
pubmed: 36117622
Curr Neurovasc Res. 2016;13(4):289-302
pubmed: 27586843
J Parkinsons Dis. 2022;12(2):495-508
pubmed: 34958046
Neurobiol Dis. 2005 Jun-Jul;19(1-2):96-107
pubmed: 15837565
Pharmaceuticals (Basel). 2022 Jan 14;15(1):
pubmed: 35056154
Behav Pharmacol. 2017 Apr;28(2 and 3-Spec Issue):142-160
pubmed: 27471947
Science. 1992 Dec 18;258(5090):1946-9
pubmed: 1470919
Antioxidants (Basel). 2022 Oct 18;11(10):
pubmed: 36290771
J Am Geriatr Soc. 2021 Jan;69(1):91-97
pubmed: 33026117
Eur Neuropsychopharmacol. 2008 May;18(5):383-9
pubmed: 18222654
Clin Gerontol. 2021 Jan-Feb;44(1):25-31
pubmed: 32223535
Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):87-105
pubmed: 30706168
Aging Ment Health. 2021 Feb;25(2):219-224
pubmed: 31603040
Clin Gerontol. 2021 Jan-Feb;44(1):32-41
pubmed: 33250007
Eur Neuropsychopharmacol. 2014 Sep;24(9):1475-82
pubmed: 25035121
Molecules. 2021 May 28;26(11):
pubmed: 34071302
Int J Mol Sci. 2021 Aug 18;22(16):
pubmed: 34445626
Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:441-463
pubmed: 32867595
J Clin Pharm Ther. 2014 Oct;39(5):564-6
pubmed: 24845114
J Clin Med. 2019 Nov 01;8(11):
pubmed: 31683817
CNS Neurol Disord Drug Targets. 2020;19(5):334-343
pubmed: 32640965
J Neuroendocrinol. 2008 May;20 Suppl 1:15-9
pubmed: 18426494
Front Pharmacol. 2020 Mar 06;11:124
pubmed: 32210795
Drugs Aging. 2019 Jan;36(1):39-51
pubmed: 30488174
Drugs Aging. 2019 Jul;36(7):655-666
pubmed: 30924098
Eur J Intern Med. 2018 Mar;49:44-50
pubmed: 29398248
J Neurosci. 2009 Feb 18;29(7):2053-63
pubmed: 19228959
Phytother Res. 2014 Jul;28(7):1007-13
pubmed: 24288245
Cochrane Database Syst Rev. 2021 Sep 17;9:CD012820
pubmed: 34532852
Syst Rev. 2022 Oct 3;11(1):210
pubmed: 36192811
Biochem Biophys Res Commun. 1995 Oct 4;215(1):89-97
pubmed: 7575630
Br J Clin Pharmacol. 2019 Sep;85(9):1888-1900
pubmed: 31222854
Cell Metab. 2013 Apr 2;17(4):475-90
pubmed: 23562074
Br J Pharmacol. 2014 Mar;171(6):1379-91
pubmed: 24102242
Trends Neurosci. 1998 Dec;21(12):521-8
pubmed: 9881850
Mov Disord Clin Pract. 2022 May 31;9(6):751-758
pubmed: 35937495
Chem Rev. 2008 May;108(5):1687-707
pubmed: 18429637
Clin Neurol Neurosurg. 2020 Sep;196:105990
pubmed: 32526487
Ann Intern Med. 2007 Jun 5;146(11):775-86
pubmed: 17548409
Epilepsy Behav Case Rep. 2017 Oct 12;9:10-11
pubmed: 29387536
Eur J Neurosci. 2009 Jun;29(11):2177-86
pubmed: 19490092
Eur J Intern Med. 2021 Jul;89:10-18
pubmed: 34083092
Drug Metab Pharmacokinet. 2012;27(3):294-300
pubmed: 22166891
Ageing Res Rev. 2014 Mar;14:56-64
pubmed: 24509411
Trends Psychiatry Psychother. 2021 Oct-Dec;43(4):243-255
pubmed: 34374269
Adv Exp Med Biol. 2019;1162:1-12
pubmed: 31332731
Animals (Basel). 2019 Sep 16;9(9):
pubmed: 31527410
Cannabis Cannabinoid Res. 2019 Dec 09;4(4):275-284
pubmed: 31872062
Molecules. 2020 Nov 07;25(21):
pubmed: 33171772
J Psychopharmacol. 2014 Nov;28(11):1088-98
pubmed: 25237116
Front Plant Sci. 2016 Feb 04;7:19
pubmed: 26870049
Int J Obes (Lond). 2006 Apr;30 Suppl 1:S7-S12
pubmed: 16570107
Nature. 1990 Aug 9;346(6284):561-4
pubmed: 2165569
PLoS One. 2011;6(12):e28668
pubmed: 22163051